{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:51:34Z","timestamp":1771923094459,"version":"3.50.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>We present a case of concurrent pulmonary aspergillosis and tuberculosis in a 53-year-old male, treated with voriconazole and rifapentine. In this case, co-administration with rifapentine resulted in a markedly lower voriconazole trough concentration (0.4\u202f\u03bcg\/mL on day 7) compared to that without it (4.3\u202f\u03bcg\/mL on day 25), reflecting a 90.7% reduction. After rifapentine was discontinued and the voriconazole dose was increased to 300\u202fmg q12h intravenously (day 8), the trough concentration remained at 0.4\u202f\u03bcg\/mL two days later (day 10). Subsequently, it increased to 3.0\u202f\u03bcg\/mL by day 14 (6\u202fdays post-adjustment) and further rose to 10.8\u202f\u03bcg\/mL by day 18 (10\u202fdays post-adjustment), exceeding the therapeutic range. The results demonstrated a significant decrease in voriconazole levels during combination therapy, an effect that persisted for over one week after rifapentine was discontinued. This case illustrates that increasing the voriconazole dose immediately after rifapentine cessation is not advisable to counteract this interaction. Furthermore, therapeutic drug monitoring should be continued even after target trough levels are attained, as the waning enzyme-induction effect may subsequently lead to supra-therapeutic exposure and potential toxicity.<\/jats:p>","DOI":"10.3389\/fmed.2026.1761845","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:16:14Z","timestamp":1769145374000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A clinically significant interaction between voriconazole and rifapentine: a case report and review of evidence"],"prefix":"10.3389","volume":"13","author":[{"given":"Tingting","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Quanzhou First Hospital","place":["Quanzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Quanzhou First Hospital","place":["Quanzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingquan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Quanzhou First Hospital","place":["Quanzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0000000000000561","article-title":"Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society","volume":"40","author":"Chen","year":"2018","journal-title":"Ther Drug Monit"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","article-title":"Clinical practice guideline for the therapeutic drug monitoring of voriconazole in Non-Asian and Asian adult patients: consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"44","author":"Takesue","year":"2022","journal-title":"Clin Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1801184","DOI":"10.1183\/13993003.01184-2018","article-title":"Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation","volume":"53","author":"Page","year":"2019","journal-title":"Eur Respir J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1345\/aph.18450","article-title":"Rifapentine: its role in the treatment of tuberculosis","volume":"33","author":"Temple","year":"1999","journal-title":"Ann Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/phar.2672","article-title":"Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management","volume":"42","author":"MacDougall","year":"2022","journal-title":"Pharmacotherapy"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2174\/0115734064260853230926080134","article-title":"An overview of various rifampicin analogs against mycobacterium tuberculosis and their drug interactions","volume":"20","author":"Asif","year":"2024","journal-title":"Med Chem"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40262-014-0144-3","article-title":"Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins","volume":"53","author":"Regazzi","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.26355\/eurrev_202304_32170","article-title":"Decreased serum voriconazole levels caused by hepatic enzyme induction after rifapentine discontinuation: a case report and literature review","volume":"27","author":"Ling","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.2147\/IDR.S461785","article-title":"The effect of rifapentine and rifampicin on serum voriconazole levels persist for 5 days and 7 days or more after discontinuation in tuberculosis patients with chronic pulmonary aspergillosis","volume":"17","author":"Lu","year":"2024","journal-title":"Infect Drug Resist"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1076266","DOI":"10.3389\/fphar.2022.1076266","article-title":"Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling","volume":"13","author":"Gra\u00f1ana-Castillo","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1093\/jac\/dku504","article-title":"Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug","volume":"70","author":"Svensson","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijantimicag.2015.12.003","article-title":"Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections","volume":"47","author":"Lamoureux","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00228-016-2089-y","article-title":"Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis","volume":"72","author":"Li","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/phar.2351","article-title":"Impact of CYP2C19 genotype and drug interactions on voriconazole plasma concentrations: a Spain pharmacogenetic-pharmacokinetic prospective multicenter study","volume":"40","author":"Blanco-Dorado","year":"2020","journal-title":"Pharmacotherapy"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1761845\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:46:15Z","timestamp":1771919175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1761845\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":17,"alternative-id":["10.3389\/fmed.2026.1761845"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1761845","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"article-number":"1761845"}}